CalciMedica, Inc. (CALC)
| Market Cap | 43.32M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -12.59M |
| Shares Out | 10.75M |
| EPS (ttm) | -1.56 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,395 |
| Open | 3.970 |
| Previous Close | 4.110 |
| Day's Range | 3.970 - 4.140 |
| 52-Week Range | 1.750 - 8.380 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 20.50 (+408.69%) |
| Earnings Date | Nov 7, 2024 |
About CALC
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company’s lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an or... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for CALC stock is "Strong Buy." The 12-month stock price forecast is $20.5, which is an increase of 408.69% from the latest price.
News
CalciMedica Announces Upcoming Late-Breaker Plenary Presentation at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting
LA JOLLA, Calif. , Oct. 16, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calci...
CalciMedica to Present at the H.C. Wainwright 26th Annual Global Investment Conference
LA JOLLA, Calif. , Sept. 3, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calci...
CalciMedica Reports Second Quarter 2024 Financial Results and Provides Clinical & Corporate Updates
Positive topline data announced from CARPO, Phase 2b trial of Auxora™ in acute pancreatitis (AP); additional data to be presented at a medical meeting later this year First patient enrolled in KOURAGE...
CalciMedica Announces First Patient Enrolled in Phase 2 KOURAGE Trial of Auxora™ in Severe Acute Kidney Injury (AKI)
Development of Auxora in AKI is supported by both clinical and pre-clinical evidence Topline data expected in 2025 LA JOLLA, Calif. , July 9, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or th...
CalciMedica Announces Presentations at Two Upcoming Healthcare Investment Conferences
LA JOLLA, Calif. , July 8, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release...
CalciMedica Set to Join Russell Microcap® Index
LA JOLLA, Calif., July 1, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-...
CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)
Primary objective of the trial met with statistically significant dose response with up to 43.6% relative reduction (2.1 day improvement) in median time to solid food tolerance versus placebo in hyper...
CalciMedica to Host Conference Call to Review Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)
Conference call and webcast to be held tomorrow, June 27, 2024 at 8:30 a.m. ET/ 5:30 a.m.
CalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate Updates
Last patient enrolled in CARPO, Phase 2b trial of Auxora™ in acute pancreatitis (AP); topline data expected in 2Q 2024 KOURAGE, Phase 2 trial in severe acute kidney injury (AKI) remains on track to in...
CalciMedica Announces Upcoming Presentation at Digestive Disease Week 2024
Collaborators from Cedars-Sinai to present human proteomics data supporting the potential benefits of Auxora™ in severe acute pancreatitis (AP) LA JOLLA, Calif., May 7, 2024 /PRNewswire/ -- CalciMedic...
CalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis
Full target enrollment of 216 patients achieved Topline data from CARPO expected in 2Q 2024 LA JOLLA, Calif., April 24, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinic...
CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates
Enrollment in CARPO, Phase 2b trial of Auxora™ in acute pancreatitis (AP), on track with topline data expected in 2Q 2024 Auxora granted Investigational New Drug clearance by the FDA for Phase 2 tria...
CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference
Therapeutic treatment with Auxora shown to hasten the recovery of kidney function and improve survival in a rat model of acute kidney injury (AKI) Preclinical results are consistent with clinical obse...
CalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference
Preclinical data show that therapeutic treatment with Auxora in a rat model of AKI improves kidney function as measured by glomerular filtration rate LA JOLLA, Calif. , Feb. 28, 2024 /PRNewswire/ -- C...
CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury
Phase 2 trial, expected to begin in 1H 2024, aims to address the unmet medical need of patients suffering from stage 2 or 3 acute kidney injury with associated acute hypoxemic respiratory failure, a c...
CalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
LA JOLLA, Calif. , Feb. 7, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calciu...
CalciMedica Announces Private Placement of up to Approximately $55 Million
$20.4 million in upfront financing with the potential to receive up to an additional approximately $34.2 million for an aggregate of up to approximately $55 million Upfront net proceeds to provide fun...
CalciMedica Reports Third Quarter 2023 Financial Results and Provides Clinical & Corporate Updates
Continued expansion of Phase 1/2 CRSPA study of Auxora™ in asparaginase-induced pancreatic toxicity (AIPT); data from initial cohort to be presented at 65th Annual American Society of Hematology (ASH...
CalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & Exposition
Auxora ™ showed a 53% reduction in days in hospital, a 40% reduction in intensive care unit (ICU) days and eliminated the need for total parenteral nutrition (TPN) LA JOLLA, Calif. , Nov. 2, 2023 /PR...
CalciMedica Announces Upcoming Presentations and Events in September
LA JOLLA, Calif. , Sept. 6, 2023 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calci...
CalciMedica to Host Acute Pancreatitis Clinical Experts Event on September 21, 2023
LA JOLLA, Calif. , Aug. 31, 2023 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calci...
CalciMedica Announces First Patient Enrolled in International Expansion of CARPO Trial of Auxora™ in Acute Pancreatitis (AP)
CARPO top-line data expected in 1H2024 CARPO enrolling in over 30 sites in the US and India LA JOLLA, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica”) (NASDAQ: CALC), a clini...
CalciMedica Announces Relisting on Nasdaq
LA JOLLA, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica”) (OTCQB: CALC), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening infl...
CalciMedica Announces Publication of Preclinical Data in Journal of Clinical Investigation (JCI) Insight Supporting the Development of CRAC Channel Inhibitors for Chronic Pancreatitis (CP)
Results support the initiation of clinical studies to assess Orai1 inhibition in patients with recurrent acute pancreatitis (RAP) and early CP
Life Biosciences Expands Team with the Appointment of Ming Yang, Ph.D., as SVP of Research and Development
BOSTON, May 23, 2023 (GLOBE NEWSWIRE) -- Life Biosciences (“Life Bio”), a biotechnology company advancing innovative cellular rejuvenation platforms to reverse diseases of aging and injury and ultimat...